Evaluation of the Efficacy and Safety of Hyaluronic Acid Injection in Labia Majora for Volume Restoration

Vulvar Atrophy Clinical Trial

— ESOLANE  

Official title:

Evaluation of the Efficacy and Safety of Hyaluronic Acid Injection in Labia Majora for Volume Restoration

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04147689
• Other study ID #: 2019-A01241-56
• Status: Completed
• Phase: N/A
• Start date: November 18, 2019
• Est. completion date: March 30, 2022

Study information

• Verified date: April 2022
• Source: Laboratoires Vivacy
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

DESIRIAL® PLUS is a CE-marketed hyaluronic acid (since 2011) whose registered indications are moderate hypotrophy, severe hypotrophy or atrophy of the vulvar Labia Majora by subcutaneous injections. The aim is to restore volume, rehydrate and add tone and tension to connective tissue areas by filling.

In this study, 71 female subjects above or equal to 18 years old at inclusion, who have moderate hypotrophy or severe hypotrophy or atrophy of the vulvar Labia Majora (according to investigator's judgement), who have given her informed consent and meet all the eligibility criteria, will be enrolled. Subjects will come to a total of 6 visits over a period of 12 months. An optional screening visit may be done before injection (additional visit). Proportion of patients having an improved perception of aesthetics (GAIS score after mirror self-examination) after baseline injection will be assessed. Global Aesthetic Improvement, Sexual function, subject's satisfaction, subject's symptoms, pain at injection and safety will be also assessed.

Description:

ESOLANE is a prospective multicenter post-marketing study of a class III medical device. This uncontrolled open-label study investigates the efficacy and safety of DESIRIAL® PLUS in volume restoration of Labia Majora. The study duration is 12 months with an optional screening visit (V0) up to 14 days before injection, the baseline visit (injection of DESIRIAL®PLUS, V1) and 5 follow-up visits after 4, 12, 24, 36 and 52 weeks (V2 to V6). At 4 weeks (V2) an optional touch-up may be done (if needed). It is envisaged to enrol 71 female patients with the wish for volume restoration in France to obtain at least 60 evaluable patients, which will be monitored over 1 year after baseline injection of DESIRIAL® PLUS.

The primary endpoint is defined as the proportion of patients having an improved perception of aesthetics (GAIS score after mirror self-examination) at 12 weeks after baseline injection of DESIRIAL® PLUS, which may be touched-up once after 4 weeks (V2).

Global Aesthetic Improvement (evaluated by the patient and the doctor), Sexual function, subject's satisfaction, subject's symptoms & pain, will be measured at all time-point with a Global Aesthetic Improvement Scale (GAIS), Female Sexual Function Index (FSFI), patient's satisfaction questionnaire (PSQ) and a Numerical Rating Scale (NRS) respectively. Safety will be also assessed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 72
• Est. completion date: March 30, 2022
• Est. primary completion date: February 25, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Women with the following conditions :

• = 18 years of age at inclusion

• Moderate hypotrophy, severe hypotrophy or atrophy of the vulvar Labia Majora, according to the investigator's judgement

• Expressed the wish for volume restoration of the Labia Majora

• Able to understand and sign the informed consent for study enrolment

• Subject affiliated to a health social security system

Non-inclusion Criteria

General :

• Pregnancy

• Breast feeding

• Known tendency to develop hypertrophic scars or keloid scars

• Participating at the same time in another clinical trial

• Deprived of their freedom by administrative or legal decision or under guardianship

Linked to inflammatory or immune status:

• Known hypersensitivity

• to one of DESIRIAL® PLUS's components (hyaluronic acid, mannitol)

• to the antiseptic solution that is planned to be used in this study

• to amide local anesthetics or to one of the components of the anesthesia product that is planned to be used in this study

• Presence of clinical signs of inflammatory in or close to the area of interest or treatment for these affections

• History of or ongoing auto-immune disease

• Suffering from hemostatic disorder

Linked to infection:

• Presence of bacterial, fungal or viral infection in or close to the area of interest or treatment for these affections

• History of streptococcal illness (such as recurrent sore throat or acute articular rheumatism)

• Recurrent genital herpes (several times a year)

Linked to neoplasia:

• History of cancer in areas close to the injection site (external urogenital, anal or vaginal)

• Actual cancer or presence of pre-cancerous cells (e.g. vaginal dysplasia)

Linked to previous or ongoing treatments:

• Under treatment with aspirin, anticoagulant, platelets aggregation inhibiting drugs, NSAIDs and Vitamin C or treated within 1 week prior to inclusion

• Under local hyaluronic acid-like hydrating treatment within 4 weeks prior to inclusion

• History of hyaluronic acid injection of >14 ml in any part of the body within the last year

• History of correction with DESIRIAL® range or other resorbable implants with similar indication within 1 year prior to inclusion

• History of correction with permanent implants including fat graft or semi-permanent in the area of injection

• Surgical history on Labia Minora within one year prior inclusion

• Surgical history on Labia Majora

Related Conditions & MeSH terms

• Atrophy
• Vulvar Atrophy

Intervention

Device:
• DESIRIAL® PLUS
DESIRIAL® PLUS is a cross-linked hyaluronic acid gel to restore volume by filling the labia majora, to rehydrate and to add tone and tension to the area of connective tissue. The baseline injection is performed at V1, with a maximum volume to be injected per labium of 2 ml. The exact volume will be determined by the physician in order to reach optimal volume correction. One optional touch-up injection of DESIRIAL® PLUS is allowed at V2 (4 weeks after Baseline), with a maximum volume to be injected per labium of 1 ml. No other touch-up injections are allowed until the end of the study.

Locations

Country	Name	City	State
France	Chu Henri Mondor	Creteil
France	Private office	Les Lilas
France	CHU Croix-Rousse	Lyon
France	Private office	Marseille
France	Centre de la femme	Nantes
France	Private office	Paris
France	Private office	Paris
France	Private office	Perpignan
France	Clinique de l'Europe	Rouen

Sponsors (1)

Lead Sponsor	Collaborator
Laboratoires Vivacy

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients having an improvement on the Global Aesthetic Improvement Scale (GAIS)	Proportion of patients having an improvement on the GAIS, evaluated by the patient (after mirror self-examination), 12 weeks after baseline injection. 5 possible grades: 1) Very much improved, 2) much improved, 3) improved, 4) no change, 5) worse	12 weeks
Secondary	Patient self-assessed aesthetic evolution	Patient self-assessed aesthetic evolution (after mirror self-examination) using GAIS evaluated 4, 24, 36 and 52 weeks after baseline injection. 5 possible grades: 1) Very much improved, 2) much improved, 3) improved, 4) no change, 5) worse	4 weeks, 24 weeks, 36 weeks, 52 weeks
Secondary	Patient aesthetic evolution	Patient aesthetic evolution evaluated by the Investigator (after visual observation) using GAIS evaluated 4, 12, 24, 36 and 52 weeks after baseline injection. 5 possible grades: 1) Very much improved, 2) much improved, 3) improved, 4) no change, 5) worse	4 weeks, 12 weeks, 24 weeks, 36 weeks, 52 weeks
Secondary	Sexual function assessment	Sexual function assessment by Female Sexual Function Index (FSFI) score self-evaluated 4, 12, 24, 36 and 52 weeks after baseline injection. Auto-questionnaire with 19 multiple choice questions to measure the sexual functioning in women	4 weeks, 12 weeks, 24 weeks, 36 weeks, 52 weeks
Secondary	Patient's satisfaction: questionnaire (PSQ)	Patient's satisfaction using a questionnaire (PSQ) evaluated 4, 12, 24, 36 and 52 weeks after baseline injection. Questionnaire with 5 questions answerable by 4 choices: not at all, a little, a lot, totally	4 weeks, 12 weeks, 24 weeks, 36 weeks, 52 weeks
Secondary	Assessment of patient's symptoms	Assessment of patient's symptoms related to atrophy or hypotrophy of the vulvar Labia Majora (irritation/burning during daily life, irritation/burning during sport, and itching) using a Numerical Rating Scale (NRS) evaluated 4, 12, 24, 36 and 52 weeks after baseline injection. Graded scale from 0 (absent) to 10 (intolerable) in increments of 1	4 weeks, 12 weeks, 24 weeks, 36 weeks, 52 weeks
Secondary	Patient's assessment of pain related to the injection	Patient's assessment of pain related to the injection, measured on a NRS during injection. Graded scale from 0 (no pain) to 10 (worst possible pain) in increments of 1	Baseline (injection)
Secondary	Report of adverses effects	Evaluation of product safety by adverse event collection throughout the study	Up to 52 weeks